You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for AZD 2066
AZD 2066 is an mGlu5 antagonist. Displays discriminative effects in rats. Orally bioavailable and brain penetrant.
Compound Libraries for AZD 2066
Technical Data for AZD 2066
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for AZD 2066
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for AZD 2066
The following data is based on the product molecular weight 381.82. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.62 mL||13.1 mL||26.19 mL|
|5 mM||0.52 mL||2.62 mL||5.24 mL|
|10 mM||0.26 mL||1.31 mL||2.62 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
References for AZD 2066
References are publications that support the biological activity of the product.
Swedberg et al (2014) AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J.Pharmacol.Exp.Ther. 350 212 PMID: 24876235
If you know of a relevant reference for AZD 2066, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: AZD 2066, AZD 2066 supplier, AZD2066, mGlu5, antagonists, metabotropic, glutamate, receptors, orally, bioavailable, brain, penetrant, Glutamate, (Metabotropic), Group, I, Receptors, 5614, Tocris Bioscience
Citations for AZD 2066
Citations are publications that use Tocris products.
Currently there are no citations for AZD 2066. Do you know of a great paper that uses AZD 2066 from Tocris? Please let us know.
Reviews for AZD 2066
There are currently no reviews for this product. Be the first to review AZD 2066 and earn rewards!
Have you used AZD 2066?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.